ResearcherGerman Cancer Research CenterNo recent work listed
Mаhmoud Youns
Matched on ORCID iD 0000-0001-8754-9634; OpenAlex author ID A5038395780.
Their work
- Papers
- 5 (first author 4, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 7
2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper
Papers 5
- Celastrol Modulates Multiple Signaling Pathways to Inhibit Proliferation of Pancreatic Cancer via DDIT3 and ATF3 Up-Regulation and RRM2 and MCM4 Down-Regulatio… First author DOI 10.2147/ott.s313933↗
- The growth inhibitory effect of gambogic acid on pancreatic cancer cells. First author DOI 10.1007/s00210-018-1485-5↗
- The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Path… First author DOI 10.1371/journal.pone.0169335↗
- Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines. Co-author DOI 10.1016/j.jprot.2012.04.042↗
- Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells. First author DOI 10.1016/j.ejphar.2010.10.026↗
Closest collaborators
The 7 strongest of 7 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Wael A. H. Hegazy · 2 shared papers, 2017–2021
- Paper The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells throu… DOI 10.1371/journal.pone.0169335↗
- Paper Celastrol Modulates Multiple Signaling Pathways to Inhibit Proliferation of Pancreatic Cancer via DDIT3 and ATF3 Up-Reg… DOI 10.2147/ott.s313933↗
- Rehab Kamel · 1 shared paper, 2018
- Jörg D. Hoheisel · 2 shared papers, 2011–2012
- Mohamed Saiel Saeed Alhamdani · 1 shared paper, 2012
- Malte Buchholz · 1 shared paper, 2012
- Andrea S. Bauer · 1 shared paper, 2012
- Thomas Mathias Gress · 1 shared paper, 2012
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.